101 related articles for article (PubMed ID: 21165398)
1. Immunological peculiarities of CD-56-positive serous ovarian adenocarcinoma.
Zueva EV; Kairbayeva MZ; Nikogosyan SO; Mozhenkova AV; Digaeva MA; Tereshkina IV; Tupitsyn NN
Bull Exp Biol Med; 2010 Oct; 149(5):604-8. PubMed ID: 21165398
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
4. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer.
Webb JR; Wick DA; Nielsen JS; Tran E; Milne K; McMurtrie E; Nelson BH
Gynecol Oncol; 2010 Sep; 118(3):228-36. PubMed ID: 20541243
[TBL] [Abstract][Full Text] [Related]
5. Gains and losses of CD8, CD20 and CD56 expression in tumor stroma-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and lymphocytes from tumor draining lymph nodes in serous papillary ovarian carcinoma patients.
Papadopoulos N; Kotini A; Cheva A; Jivannakis T; Manavis J; Alexiadis G; Lambropoulou M; Vavetsis S; Tamiolakis D
Eur J Gynaecol Oncol; 2002; 23(6):533-6. PubMed ID: 12556098
[TBL] [Abstract][Full Text] [Related]
6. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
[TBL] [Abstract][Full Text] [Related]
7. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
[TBL] [Abstract][Full Text] [Related]
8. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer.
De La Motte Rouge T; Corné J; Cauchois A; Le Boulch M; Poupon C; Henno S; Rioux-Leclercq N; Le Pabic E; Laviolle B; Catros V; Levêque J; Fautrel A; Le Gallo M; Legembre P; Lavoué V
Mol Cancer Res; 2019 Dec; 17(12):2537-2548. PubMed ID: 31537619
[TBL] [Abstract][Full Text] [Related]
9. Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma.
Townsend KN; Spowart JE; Huwait H; Eshragh S; West NR; Elrick MA; Kalloger SE; Anglesio M; Watson PH; Huntsman DG; Lum JJ
PLoS One; 2013; 8(12):e82406. PubMed ID: 24376535
[TBL] [Abstract][Full Text] [Related]
10. High density of CD66b in primary high-grade ovarian cancer independently predicts response to chemotherapy.
Posabella A; Köhn P; Lalos A; Wilhelm A; Mechera R; Soysal S; Muenst S; Güth U; Stadlmann S; Terracciano L; Droeser RA; Zeindler J; Singer G
J Cancer Res Clin Oncol; 2020 Jan; 146(1):127-136. PubMed ID: 31853662
[TBL] [Abstract][Full Text] [Related]
11. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
Pinto MP; Balmaceda C; Bravo ML; Kato S; Villarroel A; Owen GI; Roa JC; Cuello MA; Ibañez C
Gynecol Oncol; 2018 Oct; 151(1):10-17. PubMed ID: 30078505
[TBL] [Abstract][Full Text] [Related]
12. Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma.
Hagemann AR; Hagemann IS; Cadungog M; Hwang WT; Patel P; Lal P; Hammond R; Gimotty PA; Chu CS; Rubin SC; Birrer MJ; Powell DJ; Feldman MD; Coukos G
Cancer Biol Ther; 2011 Aug; 12(4):367-77. PubMed ID: 21785280
[TBL] [Abstract][Full Text] [Related]
13. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
14. [Lymphocyte activation markers in patients with ovarian cancer].
Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
[TBL] [Abstract][Full Text] [Related]
15. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.
Callahan MJ; Nagymanyoki Z; Bonome T; Johnson ME; Litkouhi B; Sullivan EH; Hirsch MS; Matulonis UA; Liu J; Birrer MJ; Berkowitz RS; Mok SC
Clin Cancer Res; 2008 Dec; 14(23):7667-73. PubMed ID: 19047092
[TBL] [Abstract][Full Text] [Related]
16. Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells.
Tonetti CR; de Souza-Araújo CN; Yoshida A; da Silva RF; Alves PCM; Mazzola TN; Derchain S; Fernandes LGR; Guimarães F
Cells; 2021 Jul; 10(7):. PubMed ID: 34359872
[TBL] [Abstract][Full Text] [Related]
17. Do tumor-infiltrating lymphocytes really indicate favorable prognosis in epithelial ovarian cancer?
Yildirim N; Akman L; Acar K; Demir S; Ozkan S; Alan N; Zekioglu O; Terek MC; Ozdemir N; Ozsaran A
Eur J Obstet Gynecol Reprod Biol; 2017 Aug; 215():55-61. PubMed ID: 28601728
[TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
[TBL] [Abstract][Full Text] [Related]
19. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites.
Ioannides CG; Platsoucas CD; Rashed S; Wharton JT; Edwards CL; Freedman RS
Cancer Res; 1991 Aug; 51(16):4257-65. PubMed ID: 1868446
[TBL] [Abstract][Full Text] [Related]
20. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
